MYE0 Stock Chart & Stats
€1.17
€0.05(4.46%)
―
--
Day’s Range― - ―
52-Week Range€0.56 - €2.02
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€129.28M
Enterprise Value€123.98M
Total Cash (Recent Filing)€14.56M
Total Debt (Recent Filing)€17.49M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding107,121,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.50Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€26.85M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained, very high gross margins reflect a scalable platform business where instruments plus proprietary consumables drive durable per-unit profitability. High product-level margins support long-term margin sustainability even as SG&A is managed, enabling leverage as revenue recovers.
Strong Cash Position And Low LeverageA large cash reserve combined with minimal or no net debt materially extends the company's runway, allowing continued investment in commercialization, product launches and SPL support without immediate refinancing risk. This bolsters resilience during a revenue trough.
Broad SPL Partner Pipeline And Recurring Revenue ModelA diversified SPL partner base and many programs underpin long-dated optionality: recurring consumables and program fees plus milestone/royalty upside create multi-year revenue levers. Installed-base consumables also provide a structural, recurring cash flow source.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow means the business consumes cash to operate; even with a strong cash balance this burn trajectory elevates medium‑term funding risk. If revenue or milestone timing slips, management may need to raise capital or reduce investment.
Declining Core Revenue And Demand PressureA sharp drop in core revenue signals structural demand headwinds for instruments, consumables and licenses; weaker renewals and lower processing/assembly sales impair the installed-base growth that normally drives recurring consumable revenue and weakens mid‑term organic recovery prospects.
Milestone Revenue Visibility Is LimitedReliance on SPL milestones creates lumpy, timing‑sensitive revenue. Management's conservative stance reduces near-term certainty around higher‑margin milestone inflows; if milestone realizations are delayed, revenue and margin recovery could be materially postponed.
MaxCyte News
MYE0 FAQ
What was MaxCyte, Inc.’s price range in the past 12 months?
MaxCyte, Inc. lowest stock price was €0.56 and its highest was €2.02 in the past 12 months.
What is MaxCyte, Inc.’s market cap?
MaxCyte, Inc.’s market cap is €129.28M.
When is MaxCyte, Inc.’s upcoming earnings report date?
MaxCyte, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 27 days.
How were MaxCyte, Inc.’s earnings last quarter?
MaxCyte, Inc. released its earnings results on May 12, 2026. The company reported -€0.035 earnings per share for the quarter, beating the consensus estimate of -€0.066 by €0.031.
Is MaxCyte, Inc. overvalued?
According to Wall Street analysts MaxCyte, Inc.’s price is currently Undervalued.
Does MaxCyte, Inc. pay dividends?
MaxCyte, Inc. does not currently pay dividends.
What is MaxCyte, Inc.’s EPS estimate?
MaxCyte, Inc.’s EPS estimate is -0.08.
How many shares outstanding does MaxCyte, Inc. have?
MaxCyte, Inc. has 107,121,670 shares outstanding.
What happened to MaxCyte, Inc.’s price movement after its last earnings report?
MaxCyte, Inc. reported an EPS of -€0.035 in its last earnings report, beating expectations of -€0.066. Following the earnings report the stock price went up 15.441%.
Which hedge fund is a major shareholder of MaxCyte, Inc.?
Currently, no hedge funds are holding shares in DE:MYE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-22.03%
Trailing 12-Months
Asset Growth
-15.43%
Trailing 12-Months
Company Description
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MYE0 Stock 12 Month Forecast
Average Price Target
€3.50